Related Experiment Video
Updated: Aug 20, 2026
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Experimental study on induction of renal cell carcinoma apoptosis by antisense oligonucleotide targeting survivin
Jian Peng1, Zhangqun Ye, Tao Zheng
1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Abstract:
The effect of antisense oligonucleotide (ASODN) targeting survivin on renal cell carcinoma (RCC) apoptosis, proliferation and sensitivity to chemotherapeutic drugs was investigated. Antisense oligonucleotide targeting survivin was designed and composed. The cDNA of survivin was transfected into RCC cell lines ACHN and 769-P, respectively. They were both cultured in normal condition. After transfection, ACHN and 769-P cell lines were cultured in a 6-well culture plate. The cultured cells were divided into 6 groups. Twenty-four h after transfection, survivin protein expression was detected by Western blot. Apoptotic index (AI) and proliferative index (PI) were examined by flow cytometry. Rate of inhibition (IR) by chemotherapeutic drugs was determined by the colorimetric MTT cell viability/proliferation assay. The results showed AI and IR of chemotherapeutic drugs in ASODN groups were significantly higher than those in the groups without ASODN. There were statistical differences between ASODN groups and control groups (P< 0.05), but there was no difference among control groups (P>0.05). The PI in the ASODN groups was significantly lower than that in the control groups with the difference being statistically significant (P<0.05). In addition, there were no differences among control groups. It was concluded that the expression of survivin could be down-regulated in 2 cell lines after ASODN transfection. Antisense oligonucleotide targeting survivin could induce RCC apoptosis, inhibit cell proliferation and sensitize RCC to chemotherapy.
Insights
Antisense oligonucleotide targeting survivin significantly increases apoptosis and chemotherapy sensitivity while reducing proliferation in renal cell carcinoma (RCC). This approach offers a promising strategy for RCC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Renal cell carcinoma (RCC) is a significant health concern.
- Survivin is a key protein involved in cancer cell survival and resistance to therapy.
- Targeting survivin presents a potential therapeutic strategy for RCC.
Purpose of the Study:
- To investigate the effect of antisense oligonucleotide (ASODN) targeting survivin on RCC.
- To evaluate the impact of ASODN on RCC apoptosis, proliferation, and chemosensitivity.
Main Methods:
- ASODN targeting survivin was designed and transfected into RCC cell lines (ACHN and 769-P).
- Survivin protein expression was assessed using Western blot.
- Apoptotic and proliferative indices were measured by flow cytometry.
- Chemotherapeutic drug sensitivity was determined using the MTT assay.
Main Results:
- ASODN transfection significantly down-regulated survivin expression in RCC cell lines.
- ASODN treatment led to a significant increase in the apoptotic index (AI).
- ASODN treatment significantly reduced the proliferative index (PI).
- ASODN enhanced the rate of inhibition (IR) of chemotherapeutic drugs.
Conclusions:
- ASODN targeting survivin effectively induces apoptosis in RCC cells.
- ASODN inhibits RCC cell proliferation.
- ASODN sensitizes RCC cells to chemotherapy, suggesting therapeutic potential.
